Technology - The in Perlo™ model:
a flexible Tumoroids and Organoids model vs Spheroids

Our technology property differentiation in twelve points:

  1. A close to zero gravity situation is maintained in the pearl and facilitates 3D tumor growth with easy microscopic readouts.
  2. 3D configuration has a high clinical relevance for all tested molecules.
  3. Pearl refractive Index of 1,33 is equivalent to water: the optical transparency enables direct tumoroid analysis performance with a confocal macroscope or hologram so to predict molecule efficiency in 8 up to 14 days, equivalent to a nude mouse.
  4. Thanks to these optical properties, one can follow the evolution of the tumoroid inside the pearl by macroscopy so to assess the impact of the tested molecule with no need to perform animal autopsies at the end of the kinetic.
  5. Solution inside the pearl is a liquid medium, thus ensuring  homogenous molecule diffusion (hydrophobic, hydrophilic substances or any biosimilar).
  6. Cost effective: our process objective is to select the most promising molecule before the in vivo step, you check the molecule performance prior to any animal testing. You reduce your animal costs; you focus only on the molecule with a higher degree of market access.
  7. No need to keep the pearl in a sterile environment: easy handling without risk of contamination and easy fusion between pearls to facilitated co-cultures, that implies lower lab cost operation.
  8. Minimized risk of drug oxidation by air (20% O2) as in 2D culture conditions.
  9. Competitive market price: our validation tests up to n=7 allow the customer to reach a robust control of the validation process during our analysis phases.
  10. We offer an opportunity to be ready for coming regulation requirement on reduction of animal testing (FDA recommendation).
  11. We need around 1mg (Vs competing processes: 1-15 grams) of material for the tests, the customer entrusts us with his molecule without risk of being copied (NMR, MS).
  12. By fusion of 2 or 3 pearls containing different phenotypic cell lines (blood, endothelium, tumor) we generate an easy creation of a cancerous organoid.